MPL and Thrombocytopenia: This could involve (1) Implementing rigorous schedule of regular blood cell counts during and after adjuvant therapy to identify trends early (2); For patients showing a propensity for myelosuppression, considering primary prophylaxis with thrombopoietin receptor agonists in subsequent lines of therapy when rechallenging with oxaliplatin is planned (3); Emphasizing dose delays, reductions, or supportive care measures over outright regimen discontinuation at the first sign of grade 2–3 thrombocytopenia, unless clinically severe or life-threatening.